Global Search

Search articles, concepts, and chapters

Graefes Arch Clin Exp OphthalmolSeptember 20205 citations

Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body.

Alfaar Ahmad Samir, Saad Anas M, KhalafAllah Mahmoud Tawfik, Elsherif Omneya Ezzat, Osman Moataz Hamed, Strauß Olaf


AI Summary

This study found that patients with prior non-Hodgkin lymphoma or skin melanoma have a significantly increased risk of developing second primary eye/adnexal cancers, necessitating careful ocular screening in cancer follow-up.

Abstract

Purpose

The eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body.

Methods

We have queried the Surveillance, Epidemiology and End-Results "SEER"-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups.

Results

Among 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere.

Conclusions

The epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin's lymphoma and melanoma as first primary.


MeSH Terms

ConjunctivaEye NeoplasmsHumansLacrimal ApparatusLymphoma, Non-HodgkinNeoplasms, Second PrimaryOrbit

Key Concepts6

Among 3,578,950 cancer patients, 1203 experienced a second malignancy of the eye and its adnexa between 1973 and 2015.

EpidemiologyCohortRetrospective Cohort Studyn=3,578,950 cancer patientsCh9

The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of patients who experienced a second malignancy of the eye and its adnexa.

EpidemiologyCohortRetrospective Cohort Studyn=1203 patients with second ocular mali…Ch9

The standardized incidence ratio (SIR) of a second malignancy of the eye and its adnexa after a prior non-Hodgkin lymphoma was 2.42.

PrognosisCohortRetrospective Cohort Studyn=3,578,950 cancer patientsCh9

The standardized incidence ratio (SIR) of a second malignancy of the eye and its adnexa after previous skin carcinomas was 3.02, after melanoma of skin was 2.13, and after oral cavity/pharynx malignancies was 1.58.

PrognosisCohortRetrospective Cohort Studyn=3,578,950 cancer patientsCh9

The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms.

PrognosisCohortRetrospective Cohort Studyn=3,578,950 cancer patientsCh9

Second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere in the body.

PrognosisCohortRetrospective Cohort Studyn=3,578,950 cancer patientsCh9

Is this article assigned to the wrong chapter(s)? Let us know.